Design, synthesis and antimicrobial activities of some new quinoline derivatives carrying 1,2,3-triazole moiety

European Journal of Medicinal Chemistry

Volumn 45, Issue 9, 2010, Pages 3803-3810

  Thomas, K D ^a,b   Adhikari, Airody Vasudeva ^b   Shetty, N Suchetha ^c  

^a Anthem Biosciences Pvt Ltd   (India)

^b NATIONAL INSTITUTE OF TECHNOLOGY KARNATAKA   (India)

^c NITTE DEEMED TO BE UNIVERSITY   (India)

Author keywords

1,2,3 Triazole; Antibacterial activity; Antifungal activity; Quinoline

Indexed keywords

1 [1 (6 METHOXY 2 METHYLQUINOLIN 4 YL) (1H) 1,2,3 TRIAZOL 4 YL] N,N DIMETHYL METHANAMINE; 1 [4 [[1 (6 METHOXY 2 METHYLQUINOLIN 4 YL) (1H) 1,2,3 TRIAZOL 4 YL]METHYL]PIPERAZIN 1 YL]ETHANONE; 4 [4 [(4 CYCLOHEXYLPIPERAZIN 1 YL)METHYL] (1H) 1,2,3 TRIAZOL 1 YL] 6 METHOXY 2 METHYLQUINOLINE; 4 [4 [(4 ETHYLPIPERAZIN 1 YL)METHYL] (1H) 1,2,3 TRIAZOL 1 YL] 6 METHOXY 2 METHYL QUINOLINE; 4 [4 [(4 ETHYLPIPERAZIN 1 YL)METHYL] (1H) 1,2,3 TRIAZOL 1 YL] 6 METHOXY 2 METHYLQUINOLINE; 4 [4 [(4 ISOPROPYLPIPERAZIN 1 YL)METHYL] (1H) 1,2,3 TRIAZOL 1 YL] 6 METHOXY 2 METHYLQUINOLINE; 4 [4 [[4 (2 FLUOROPHENYL)PIPERAZIN 1 YL]METHYL] (1H) 1,2,3 TRIAZOL 1 YL] 6 METHOXY 2 METHYLQUINOLINE; 4 [4 [[4 (4 FLUOROPHENYL)PIPERAZIN 1 YL]METHYL] (1H) 1,2,3 TRIAZOL 1 YL] 6 METHOXY 2 METHYLQUINOLINE; 6 METHOXY 2 METHYL 4 [4 [(4 METHYLPIPERAZIN 1 YL)METHYL] (1H) 1,2,3 TRIAZOL 1 YL]QUINOLINE; 6 METHOXY 2 METHYL 4 [4 [(4 MORPHOLINOPIPERIDIN 1 YL)METHYL] (1H) 1,2,3 TRIAZOL 1 YL]QUINOLINE; 6 METHOXY 2 METHYL 4 [4 [(4 P TOLYLPIPERAZIN 1 YL)METHYL] (1H) 1,2,3 TRIAZOL 1 YL]QUINOLINE; 6 METHOXY 2 METHYL 4 [4 [(4 PHENYLPIPERAZIN 1 YL)METHYL] (1H) 1,2,3 TRIAZOL 1 YL]QUINOLINE; 6 METHOXY 2 METHYL 4 [4 [(PIPERIDIN 1 YL)METHYL] (1H) 1,2,3 TRIAZOL 1 YL]QUINOLINE; 6 METHOXY 2 METHYL 4 [4 [(PYRROLIDIN 1 YL)METHYL] (1H) 1,2,3 TRIAZOL 1 YL]QUINOLINE; 6 METHOXY 4 [4 [(4 (4 METHOXYPHENYL) PIPERAZIN 1 YL)METHYL] (1H) 1,2,3 TRIAZOL 1 YL] 2 METHYLQUINOLINE; 6 METHOXY 4 [4 [[4 (4 METHOXY 2 METHYLPHENYL)PIPERAZIN 1 YL]METHYL] (1H) 1,2,3 TRIAZOL 1 YL] 2 METHYLQUINOLINE; CICLOPIROXOLAMINE; CIPROFLOXACIN; N [1 (6 METHOXY 2 METHYLQUINOLIN 4 YL) (1H) 1,2,3 TRIAZOL 4 YL]METHYL CYCLOPROPANAMINE; N [1 (6 METHOXY 2 METHYLQUINOLIN 4 YL) (1H) 1,2,3 TRIAZOL 4 YL]METHYLAMINE; N [[1 (6 METHOXY 2 METHYLQUINOLIN 4 YL) (1H) 1,2,3 TRIAZOL 4 YL]METHYL]BUTAN 2 AMINE; N [[1 (6 METHOXY 2 METHYLQUINOLIN 4 YL) (1H) IMIDAZOL 4 YL]METHYL]CYCLOHEXANAMINE; N [[1 (6 METHOXY 2 METHYLQUINOLIN 4 YL) (1H) IMIDAZOL 4 YL]METHYL]CYCLOPENTANAMINE; N ETHYL N [[1 (6 METHOXY 2 METHYLQUINOLIN 4 YL) (1H) 1,2,3 TRIAZOL 4 YL]METHYL]ETHANAMINE; N1 [[1 (6 METHOXY 2 METHYLQUINOLIN 4 YL) (1H) 1,2,3 TRIAZOL 4 YL]METHYL] N1,N2,N2 TRIMETHYLETHANE 1,2 DIAMINE; N1 [[1 (6 METHOXY 2 METHYLQUINOLIN 4 YL) (1H) 1,2,3 TRIAZOL 4 YL]METHYL] N3,N3 DIIMETHYLPROPANE 1,3 DIAMINE; QUINOLINE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIFUNGAL ACTIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; BACTERIAL STRAIN; BACTERIUM CULTURE; CANDIDA ALBICANS; CONTROLLED STUDY; DRUG DESIGN; DRUG STRUCTURE; DRUG SYNTHESIS; ESCHERICHIA COLI; FUNGAL STRAIN; INFRARED SPECTROSCOPY; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PENICILLIUM MARNEFFEI; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PYOGENES; TRICHOPHYTON MENTAGROPHYTES;

AMINES; ANILINE COMPOUNDS; ANTI-INFECTIVE AGENTS; BACTERIA; DRUG DESIGN; FUNGI; MICROBIAL SENSITIVITY TESTS; QUINOLINES; TRIAZOLES;

EID: 77955559753     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2010.05.030     Document Type: Article

References (35)

1. National Nosocomial Infections Surveillance (NNIS) System Am. J. Infect. Control 32 2004 470 485
2. H. Goossens Chemotherapy 51 2005 177 181
3. D. Styers, D.J. Sheehan, P. Hogan, and D.F. Sahm Ann. Clin. Microbiol. Antimicrob. 5 2006 2 (Online journal published by Biomed Central)
4. Antimicrobial resistance prevention initiative Am. J. Infect. Control 34 5Suppl 2006 A1 S79
5. M.P. LaMontagne, A.M.S. Markovac, and M. Sami Khan J. Med. Chem. 25 1982 964 968
6. M.P. LaMontagne, P. Blumbergs, and R.E. Strube J. Med. Chem. 25 1982 1094 1097
7. P. Nasveld, and S. Kitchener Trans. R. Soc. Trop. Med. Hyg. 99 2005 2 5
8. A. Mahamoud, J. Chevalier, A. Davin-Regli, J. Barbe, and Jean-Marie Pages Curr. Drug Targets 7 2006 843 847
9. S. Eswaran, A.V. Adhikari, and N.S. Shetty Eur. J. Med. Chem. 44 2009 4637 4647
10. W.A. Denny, W.R. Wilson, D.C. Ware, G.J. Atwell, J.B. Milbank, R.J. Stevenson. U.S Patent 7064117 (2006).
11. P.A. Leatham, H.A. Bird, V. Wright, D. Seymour, and A. Gordon Eur. J. Rheumatol. Inflamm. 6 1983 209 211
12. N. Muruganantham, R. Sivakumar, N. Anbalagan, V. Gunasekaran, and J.T. Leonard Biol. Pharm. Bull. 27 2004 1683 1687
13. M.P. Maguire, K.R. Sheets, K. McVety, A.P. Spada, and A. Zilberstein J. Med. Chem. 37 1994 2129 2137
14. W.D. Wilson, M. Zhao, S.E. Patterson, R.L. Wydra, L. Janda, and L. Strekowski Med. Chem. Res. 2 1992 102 110
15. L. Strekowski, J.L. Mokrosz, V.A. Honkan, A. Czarny, M.T. Cegla, S.E. Patterson, R.L. Wydra, and R.F. Schinazi J. Med. Chem. 34 1991 1739 1746
16. K. Kacprzak Synlett 6 2005 943 946
17. D.R. Buckle, and C.J.M. Rockell J. Chem. Soc., Perkin Trans. 1 1982 627 630
18. D.R. Buckle, D.J. Outred, C.J.M. Rockell, H. Smith, and B.A. Spicer J. Med. Chem. 26 1983 251 254
19. D.R. Buckle, C.J.M. Rockell, H. Smith, and B.A. Spicer J. Med. Chem. 29 1986 2262 2267
20. M.J. Genin, D.A. Allwine, D.J. Anderson, M.R. Barbachyn, D.E. Emmert, S.A. Garmon, D.R. Graber, K.C. Grega, J.B. Hester, D.K. Hutchinson, J. Morris, R.J. Reischer, C.W. Ford, G.E. Zurenko, J.C. Hamel, R.D. Schaadt, D. Stapert, and B.H. Yagi J. Med. Chem. 43 2000 953 970
21. G.A. Nilkanth, S.P. Vandana, N.M. Nripendra, Awanit Kumar, K.S. Praveen, Aanchal Sharma, and K.B. Manoj Bioorg. Med. Chem. Lett. 19 2009 759 763
22. R. Alvarez, S. Velazquez, A. San-Felix, S. Aquaro, E. De Clercq, C.-F. Perno, A. Karlsson, J. Balzarini, and M.J. Camarasa J. Med. Chem. 37 1994 4185 4194
23. J.L. Kelley, C.S. Koble, R.G. Davis, E.W. McLean, F.E. Soroko, and B.R. Cooper J. Med. Chem. 38 1995 4131 4134
24. G. Biagi, G. Dell'Omodarme, M. Ferretti, I. Giorgi, O. Livi, and V. Scartoni Farmacognosia 45 1990 1181 1192
25. G. Biagi, O. Livi, V. Scartoni, A. Lucacchini, and M.R. Mazzoni Farmacognosia 41 1986 597 610
26. R.G. Micetich, S.N. Maiti, P. Spevak, T.W. Hall, S. Yamabe, N. Ishida, M. Tanaka, T. Yamazaki, A. Nakai, and K. Ogawa J. Med. Chem. 30 1987 1469 1474
27. H.C. Kolb, and K.B. Sharpless Drug Discov. Today 8 2003 1128 1137
28. J. Xie, and C.T. Seto Bioorg. Med. Chem. 15 2007 458 473
29. Z.-Y. Yan, Y.-B. Zhao, M.-J. Fan, W.-M. Liu, and Y.-M. Liang Tetrahedron 61 2005 9331 9337
30. A.L. Barry Procedure for testing antimicrobial agents in agar media V.L. Corian, Antibiotics in Laboratory Medicine 1980 Williams and Wilkins Baltimore, MD 1 23
31. D. James, Mac. Lowry, J.M. Jaqua, and T.S. Sally Appl. Microbiol. 20 1970 46 53
32. C.H. Fenlon, and M.H. Cynamon Antimicrob. Agents Chemother. 29 1986 386 388
33. R. Davis, A. Markham, and J.A. Balfour Ciprofloxacin, an updated review of its pharmacology, therapeutic efficacy and tolerability Drugs 51 1996 1019 1074
34. B.A. Arthington-Skaggs, M. Moltely, D.W. Warnock, and C.J. Morrison J. Clin. Microbiol. 2000 2254 2260
35. R.S. Verma, Z.K. Khan, A.P. Singh, Antifungal Agents: Past, Present and Future Prospects 1998 National Academy of Chemistry and Biology Lucknow, India 55 128